By accessing this site, you agree we are not liable, whether in contract, tort (including negligence) or otherwise, in respect of any damage, expense or other loss you may suffer arising out of such information or any reliance you may place upon such information from this site.
Industry: Biotechnology
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
Institution %: 88.833
YTD Institution change: 1721084
InsidersInsiders %: 4.43
Insiders Purchases YTD: 120071
Insiders Sales YTD: 87547
Insiders Net YTD: 32524
Analyst RatingsTarget Price: 180.61
Overall Rating: 4.2381
Strong Buys (5): 9
Buys (4): 8
Holds (3): 4
Sells (2): 0
Strong Sells (1): 0
52 Week Hi: 173.25
52 Week Low: 55.25
Beta: 0.884
50 Day MA: 137.5626
200 Day MA: 118.5156
Earnings / Revenue TrendsQtr Earnings Growth YOY: 0
Qtr Revenue Growth YOY: 0.631
Forward PE:
Trailing PE: